Serum soluble Fas and Fas ligand (FasL) in primary Sjögren’s syndrome

Research output: Contribution to journal › Letter › Research › peer-review

Original language	English
Pages (from-to)	S254-S256
Number of pages	3
Journal	Clinical and Experimental Rheumatology
Volume	37
Issue number	118
Publication status	Published - 1 May 2019

Access to Document

@article{c94034b477af417fab4485a2b735204f,

title = "Serum soluble Fas and Fas ligand (FasL) in primary Sj{\"o}gren{\textquoteright}s syndrome",

author = "F.B. Vincent and M. Bubicich and Sarah Downie-Doyle and Fabienne Mackay-Fisson and Morand, \{Eric F.\} and Maureen Rischmueller",

year = "2019",

month = may,

day = "1",

language = "English",

volume = "37",

pages = "S254--S256",

journal = "Clinical and Experimental Rheumatology",

issn = "0392-856X",

publisher = "Clinical and Experimental Rheumatology",

number = "118",

}

TY - JOUR

T1 - Serum soluble Fas and Fas ligand (FasL) in primary Sjögren’s syndrome

AU - Vincent, F.B.

AU - Bubicich, M.

AU - Downie-Doyle, Sarah

AU - Mackay-Fisson, Fabienne

AU - Morand, Eric F.

AU - Rischmueller, Maureen

PY - 2019/5/1

Y1 - 2019/5/1

UR - https://www.scopus.com/pages/publications/85071646632

M3 - Letter

C2 - 30789150

AN - SCOPUS:85071646632

SN - 0392-856X

VL - 37

SP - S254-S256

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

IS - 118

ER -